PK/PD modeling is essential for understanding ADMET properties, optimizing dosing regimens, and reducing late-stage attrition rates in drug development. AI/ML algorithms enhance PK/PD modeling by ...
Combined therapy of EGFR TKI and VEGFR TKI may produce a greater therapeutic benefit and overcome EGFR TKI-induced resistance. However, a previous study shows that a combination of EGFR TKI erlotinib ...
Phase I study of everolimus (E; RAD001) + low-dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results This is an ASCO Meeting Abstract from the 2009 ASCO Annual Meeting ...
Bioavailability of the hedgehog pathway inhibitor GDC-0449 in a phase I pharmacokinetic (PK) study in healthy female subjects. Background: Serdemetan is a compound that can cause replicative stress ...
PRINCETON, N.J.--(BUSINESS WIRE)--Certara®, the global leader in model-informed drug development, regulatory science, market access and real-world evidence services, today announced the launch of ...
One PK/PD model helps researchers predict the disposition of a drug from the body and its penetration to the target organs. The model incorporates data from animal tests on the new drug and on a ...
Y-mAbs presented preclinical PK data for CD38-SADA at the 2025 AACR Annual Meeting, supporting its cancer treatment development. Y-mAbs Therapeutics, Inc. announced the presentation of preclinical and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback